Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort
Phase 4
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: Saline
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT05957653
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia
Phase 2
Not yet recruiting
- Conditions
- Chemotherapy-Induced Thrombocytopenia
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT05944211
The Difference Between Daily and Alternative Day Use of Icodextrin
Phase 4
Not yet recruiting
- Conditions
- Peritoneal Dialysis Solution Adverse Reaction
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT05943470
Multiomics Study of Fibrosis Factors After Liver Transplantation and Exploration of Fibrosis Methylation Biomarkers
Not yet recruiting
- Conditions
- Liver Fibrosis
- Interventions
- Other: Liver allograft fibrosis
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05926778
- Locations
- 🇨🇳
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
Not Applicable
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: CAR-GPC3 T cells
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05926726
- Locations
- 🇨🇳
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients
Phase 2
Recruiting
- Conditions
- Upper Urinary Tract Urothelial CarcinomaKidney PreservationPD-1antibodyHER-2 ADC
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05912816
- Locations
- 🇨🇳
Ethics Committee of Shanghai Renji Hospital, Shanghai, Shanghai, China
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 488
- Registration Number
- NCT05910398
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases
Not yet recruiting
- Conditions
- Extrahepatic Bile Duct CancerGall StoneGallbladder CancerBiliary Tract NeoplasmsBiliary Tract DiseasesIntrahepatic Cholangiocarcinoma
- Interventions
- Other: no interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05896956
Smart Flex Stent System for the Treatment Long Femoropopliteal Artery Lesions
Not Applicable
Recruiting
- Conditions
- Peripheral Arterial Disease
- Interventions
- Device: Smart flex stent
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05894863
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC
Phase 2
Recruiting
- Conditions
- Fumarate Hydratase Deficient Renal Cell Carcinoma
- Interventions
- Biological: Tislelizumab
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05877820
- Locations
- 🇨🇳
Ethics Committee of Shanghai Renji Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath